AVASTIN (bevacizumab), monoclonal antibody
Reason for request
Extension of Inclusion
Date 01 April 2015
No clinical added value demonstrated in treatment of the first recurrence of platinum-sensitive ovarian cancer or the recurrence of platinum-resistant ovarian cancer.
- AVASTIN has Marketing Authorisation :
- in combination with carboplatin and gemcitabine, in the treatment of the first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer ;
in combination with paclitaxel, with topotecan or with pegylated liposomal doxorubicin, in the case of recurrence of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
- The addition of bevacizumab to the chemotherapy has been shown to have a moderate effect on progression-free survival, without a demonstrated increase in overall survival and quality of life but with an increase in toxicity, particularly vascular toxicity.
Improvement in actual benefit